Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
Dosage Regimen Designs: Nomograms and Tabulations01:23

Dosage Regimen Designs: Nomograms and Tabulations

Nomograms and tabulations are vital tools used by clinicians to design accurate and individualized dosage regimens. These instruments provide a straightforward method for adjusting dosages based on individual patient characteristics, including age, weight, and physiological condition. The foundation of a drug's nomogram is population pharmacokinetic data collected and analyzed using specific models. This data simplifies complex equations, presenting them diagrammatically or tabularly for easy...
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discrepancies in the therapeutic indications granted by the European Medicines Agency and the US Food and Drug Administration for new cancer drugs: An analysis of potential explanations.

Journal of cancer policy·2025
Same author

Cancer drug applications to the EMA and the FDA: A comparison of new drugs and extension of indication in terms of approval decisions and time in review.

British journal of clinical pharmacology·2025
Same author

Establishment of a children's Drugs and Therapeutics Committee to ensure evidence-based and cost-effective medical treatment for children.

British journal of clinical pharmacology·2023
Same author

Medication changes implemented during medication reviews and factors related to deprescribing: Posthoc analyses of a randomized clinical trial in geriatric outpatients with polypharmacy.

British journal of clinical pharmacology·2023
Same author

Treatment effect modifiers in hospitalised patients with COVID-19 receiving remdesivir and dexamethasone.

Infectious diseases (London, England)·2023
Same author

Use of Therapeutic Drug Monitoring in Amiodarone Treatment: A Systematic Review of Recent Literature.

Therapeutic drug monitoring·2023
Same journal

[Mosaicism as a cause of Cowden syndrome].

Ugeskrift for laeger·2026
Same journal

[Thyrotoxic crisis with cardiogenic shock].

Ugeskrift for laeger·2026
Same journal

[Mindfulness-based cognitive therapy in the treatment of depression].

Ugeskrift for laeger·2026
Same journal

[Fitness].

Ugeskrift for laeger·2026
Same journal

[Risk of developing cataract related to fluoroscopy].

Ugeskrift for laeger·2026
Same journal

[Obturator hernia with small bowel ileus presenting as hip pain in an elderly woman].

Ugeskrift for laeger·2026
See all related articles

Related Experiment Video

Updated: Jun 20, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

[Changing clinicians' prescription patterns].

Lene Ørskov Reuther1, Hanne Rolighed Christensen, Camilla Mikkelsen

  • 1Klinisk Farmakologisk Enhed, Bispebjerg Hospital, DK-2400 København NV. lenereuther@hotmail.com

Ugeskrift for Laeger
|September 18, 2009
PubMed
Summary
This summary is machine-generated.

The Central Drug Committee reduced costs by shifting prescriptions from expensive etanercept and adalimumab to infliximab, a cheaper tumor necrosis factor alpha (TNF-alpha) inhibitor. This intervention successfully lowered healthcare expenditure on biologic therapies.

More Related Videos

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Related Experiment Videos

Last Updated: Jun 20, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Area of Science:

  • Pharmacoeconomics
  • Health Services Research
  • Immunology

Context:

  • Rising healthcare expenditure on biologic therapies, specifically tumor necrosis factor alpha (TNF-alpha) inhibitors, was observed in Copenhagen County hospitals starting in 2005.
  • Three TNF-alpha inhibitors (etanercept, adalimumab, and infliximab) were identified as major contributors to this trend.
  • Etanercept and adalimumab were noted to be twice as expensive as infliximab, despite comparable efficacy and safety profiles.

Purpose:

  • To evaluate the impact of a targeted intervention by the Central Drug Committee on the prescribing patterns of TNF-alpha inhibitors.
  • To assess the cost-effectiveness of shifting prescriptions towards less expensive biologic agents.
  • To analyze changes in clinical practice in response to formulary or guideline adjustments.

Summary:

  • The Central Drug Committee, in collaboration with Copenhagen County hospitals (H:S), intervened to address increasing use and expenditure of TNF-alpha inhibitors.
  • The intervention focused on promoting the use of infliximab over the more expensive etanercept and adalimumab, which have similar efficacy and safety.
  • A modest effort by the committee successfully altered clinicians' prescription patterns, leading to a more cost-effective utilization of these therapies.

Impact:

  • Demonstrated successful implementation of a cost-saving strategy in biologic drug prescribing.
  • Provided a model for influencing clinical practice towards pharmacoeconomically sound decisions.
  • Contributed to reducing overall healthcare expenditure on TNF-alpha inhibitors within the studied region.